论文部分内容阅读
目的探讨培菲康对原发性高脂血症(EHL)患者的临床疗效及血脂变化的影响。方法选择102例EHL患者为研究对象,随机分为对照组和观察组各51例。对照组口服阿托伐他汀钙胶囊10mg/d,睡前口服。观察组采用培菲康2.0g/次,3次/d,饭后半小时温水服用。12周为一疗程,比较两组患者治疗前后血脂水平及治疗效果。结果观察组临床控制率为31.37%,对照组为13.73%,差异有统计学意义(P<0.05);观察组总有效率(94.12%)显著高于对照组(76.47%),差异有统计学意义(P<0.01)。治疗后两组血脂水平均改善,但观察组TG、TC、LDL-C水平低于对照组(P<0.01),HDL-C水平高于对照组(P<0.01)。治疗后随访6个月,对照组复发率为27.45%,观察组为5.88%,两组差异有统计学意义(P<0.01)。结论培菲康对血脂水平的改善优于阿托伐他汀钙,患者复发率低,且无明显不良反应。
Objective To investigate the effect of Peifeikang on clinical efficacy and blood lipid changes in patients with primary hyperlipidemia (EHL). Methods A total of 102 patients with EHL were selected as study subjects and randomly divided into control group and observation group with 51 cases each. The control group oral atorvastatin calcium capsules 10mg / d, orally before going to bed. Observation group using Pefeiconazole 2.0g / time, 3 times / d, half an hour after taking warm water. 12 weeks for a course of treatment, compared two groups of patients before and after treatment of blood lipid levels and treatment. Results The clinical control rate was 31.37% in observation group and 13.73% in control group, the difference was statistically significant (P <0.05). The total effective rate (94.12%) in observation group was significantly higher than that in control group (76.47%), the difference was statistically Significance (P <0.01). After treatment, the levels of serum lipids in both groups were improved, but the levels of TG, TC and LDL-C in the observation group were lower than those in the control group (P <0.01). The levels of HDL-C in the observation group were higher than those in the control group (P <0.01). After 6 months of follow-up, the recurrence rate was 27.45% in the control group and 5.88% in the observation group, with significant difference between the two groups (P <0.01). Conclusion Pefikan improved blood lipids better than atorvastatin calcium, with low recurrence rate and no obvious adverse reactions.